Caisse DE Depot ET Placement DU Quebec Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• The Caisse DE Depot ET Placement DU Quebec has reduced its stake in Regeneron Pharmaceuticals by **28.2%**, selling **87,539 shares**, and now holds **222,614 shares** valued at approximately **$141,188,000**.
• Regeneron Pharmaceuticals posted **earnings per share (EPS)** of **$12.89** for the latest quarter, significantly exceeding analyst expectations of **$8.43**, with a reported revenue of **$3.68 billion**.
• The company declared a quarterly dividend of **$0.88**, with a **dividend yield** of **0.6%** and an annualized payout of **$3.52**.

Caisse DE Depot ET Placement DU Quebec trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 222,614 shares of the biopharmaceutical company's stock after selling 87,539 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 0.20% of Regeneron Pharmaceuticals worth $141,188,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the period. KBC Group NV grew its position in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares during the last quarter. Finally, Lmcg Investments LLC grew its position in Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after acquiring an additional 10,110 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:REGN traded up $1.09 on Friday, reaching $580.70. The company had a trading volume of 573,977 shares, compared to its average volume of 1,103,987. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,210.97. The firm's 50 day simple moving average is $555.84 and its 200-day simple moving average is $588.67. The firm has a market capitalization of $61.55 billion, a PE ratio of 14.63, a PEG ratio of 1.96 and a beta of 0.33. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 EPS. The business's revenue was up 3.6% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday. Citigroup restated a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Jefferies Financial Group lifted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.